来自MSN2 分钟
Arvinas, Inc. (NASDAQ:ARVN) Q4 2024 Earnings Call Transcript
ARV-393 has demonstrated significant anti-tumor activity in numerous preclinical in vivo models of non-Hodgkin lymphoma. We ...